Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by palinc2000on Oct 12, 2024 4:22pm
72 Views
Post# 36264112

RE:RE:Question on back up facility for Egrifta

RE:RE:Question on back up facility for EgriftaMy point was why did Levesque ask Dubuc to reply to thos very very fundamental question,,,,,
The decision not to have a back up facility is under the CEo s responsibilty and it really bothers me that he had to rely on the CFO to reply,

scarlet1967 wrote:

"We do not own or operate manufacturing facilities for the production of EGRIFTA S/® and tesamorelin, nor do we have plans to develop our own manufacturing operations in the foreseeable future. We currently rely on Bachem and Jubilant to manufacture and supply all of our required raw materials, drug substance and drug product for sales of EGRIFTA S/®. We will also rely on a single third-party supplier, Lyophilization Services of New England ("LSNE") for the manufacture of the F8 Formulation. We have not qualified alternative manufacturers to date and no assurance can be given that such manufacturers will be qualified in the future or receive necessary approvals. There are a limited number of third-party suppliers that are compliant with current good manufacturing practice, ("GMP"), and that also have the necessary expertise and capacity to manufacture our drug substance and drug product."

They don't have a back up manufacturer for Egrifta SV and will be relying on a "single supplier for F8" despite the fact that Egrifta is absolutely their main commercial product.

https://www.theratech.com/static-files/e2cd4c2e-6d00-4f3d-9197-f588856fa98e



palinc2000 wrote: Levesque did not provide an answer and he asked Dubuc to reply.....
Same reaction for other questions on other subjects
He and Kamala have things in common !!!





 



<< Previous
Bullboard Posts
Next >>